Alzheimers is a neurodegenerative disorder that mostly occurs with aging and is a leading cause of dementia. The global Alzheimers disease market has observed tremendous growth in the recent years, owing to the high prevalence of Alzheimers disease and increased life expectancy of population.
Rising old age population and higher incidences of neurodegenerative diseases are two significant factors that supplement the Alzheimers Disease Therapeutics and Diagnostics Market growth. Moreover, increasing R&D investment and a large number of drugs in the pipeline are further expected to fuel the market growth. However, high cost of treatment and lack of transparent reimbursements are likely to curtail the market growth.
Alzheimers patients are generally diagnosed in the late stage, mostly due to delayed appearance of symptoms. Hence, developing the early diagnostic devices would be a significant challenge for the diagnostic device makers.
The Alzheimers Disease Therapeutics and Diagnostics Market is segmented on the basis of therapeutics, diagnostics and geography. According to the therapeutics, the market is segmented into, marketed drugs such as Cholinesterase inhibitors and NMDA receptor antagonist, and Pipeline Drugs. On the basis of diagnostics, the market is segmented into Lumbar puncture test, Computed tomography (CT) scan, Magnetic resonance imaging (MRI), Electroencephalography (EEG), Positron emission tomography (PET) scan and Others. Geographically, the market is segmented across four regions namely North America, Europe, Asia Pacific, and LAMEA.
Get the PDF brochure of this market insight@ https://www.alliedmarketresearch.com/request-toc-and-sample/1441
The research collaborations and new product launches are some of the key strategies adopted by leading industry players. For instance, Actavis plc in collaboration with Adamas Pharmaceuticals Inc. recently announced the US FDA approval of Namzaric, a fixed-dose combination of memantine and donepezil. The drug is expected to be launched in the first half of year 2015. Further, in Jan 2015, Johnson & Johnson signed a research deal with a Swiss biotech firm AC Immune, to develop anti-tau Alzheimer’s vaccines.
KEY MARKET SEGMENTS:
The Alzheimers Disease Therapeutics and Diagnostics Market is segmented below:
Alzheimers Disease Therapeutics and Diagnostics Market By Therapeutics
- Marketed Drugs
- Cholinesterase inhibitors
- NMDA receptor antagonist
- Pipeline Drugs
Alzheimers Disease Therapeutic and Diagnostic Market By Diagnostics
- Lumbar puncture test
- Computed tomography (CT) scan
- Magnetic resonance imaging (MRI)
- Electroencephalography (EEG)
- Positron emission tomography (PET) scan